Mixed model of determinants of PGA−PhGA in 401 patients with early axSpA over six visits
| Variable | Estimate (95% CI) | p Value |
|---|---|---|
| Intercept | –0.959 (–0.972 to –0.946) | 0.0027 |
| Age | 0.0070 (0.0067 to 0.0073) | 0.35 |
| Sex (female) | 0.0104 (0.055 to 0.015) | 0.93 |
| Ethnicity (Caucasian) | –0.119 (–0.128 to –0.110) | 0.59 |
| Level of education (postsecondary) | –0.078 (–0.084 to –0.072) | 0.59 |
| Paid work status | 0.044 (0.038 to 0.050) | 0.76 |
| ASAS axial criteria fulfilled20 | 0.166 (0.160 to 0.171) | 0.31 |
| CRP>5 mg/L | –0.141 (–0.145 to –0.137) | 0.15 |
| BASFI (0–100) | –0.00001 (–0.0002 to 0.0001) | 0.99 |
| BASDAI components (0–10) | ||
| Fatigue | 0.131 (0.130 to 0.132) | <0.001 |
| Spine pain | 0.240 (0.239 to 0.241) | <0.001 |
| Joints pain | 0.0211 (0.0202 to 0.0219) | 0.33 |
| Enthesitis pain | 0.0868 (0.0077 to 0.0096) | 0.71 |
| Morning stiffness | –0.040 (–0.041 to –0.039) | 0.10 |
Bold print: significant results.
axSpA, axial spondyloarthritis; ASAS, Assessment of SpondyloArthritis international Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; PGA, patient global assessment; PhGA, physician global assessment.